Susan M. Geyer

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Discordance between central versus local response assessments in neuroendocrine tumor (NET) patients (pts) enrolled in A021202.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.3_suppl.361

Top 100%

0DataRank

Top 100%0 citations

Michelle R. Mahoney, Timothy R. Asmis, Nathan C. Hall, Sanja Karovic, Michael V. Knopp +9 more

Papers

Driven by 25 papers — median percentile 0. Top paper: “Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors”.

Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors

New England Journal of Medicine(2024)10.1056/nejmoa2403991

N/A

3.0DataRank · unranked

141 citations

Susan M. Geyer, Tyler Zemla, Michael V. Knopp, Spencer C. Behr, Sydney Pulsipher +19 more

Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801

Blood Advances(2020)10.1182/bloodadvances.2019000492

N/A

2.8DataRank · unranked

72 citations

Susan M. Geyer, Kristina Laumann, Weiqiang Zhao, Donna Bucci, Geoffrey L. Uy +12 more

Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial

Blood Advances(2020)10.1182/bloodadvances.2020002904

N/A

1.5DataRank · unranked

61 citations

Richard A. Larson, Dan Jones, Guido Marcucci, Thomas W. Prior, Jürgen Krauter +32 more

Alliance A071401: Phase II trial of FAK inhibition in meningiomas with somatic NF2 mutations.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.2502

N/A

0.964DataRank · unranked

24 citations

Erin Twohy, Elizabeth R. Gerstner, Timothy J. Kaufmann, A. John Iafrate, Suriya Jeyapalan +16 more

Myeloablative vs nonmyeloablative consolidation for primary central nervous system lymphoma: results of Alliance 51101

Blood Advances(2024)10.1182/bloodadvances.2023011657

N/A

0.691DataRank · unranked

26 citations

Sharmila Giri, Amy S. Ruppert, Susan M. Geyer, Scott E. Smith, Nimish Mohile +11 more

CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma

Cancer Research Communications(2024)10.1158/2767-9764.crc-22-0516

N/A

0.216DataRank · unranked

2 citations

Susan M. Geyer, Andrew B. Nixon, Federico Innocenti, Qian Shi, Priya Kumthekar +16 more

Discordance between central versus local response assessments in neuroendocrine tumor (NET) patients (pts) enrolled in A021202.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.3_suppl.361

Top 100%

0DataRank

Top 100%0 citations

Michelle R. Mahoney, Timothy R. Asmis, Nathan C. Hall, Sanja Karovic, Michael V. Knopp +9 more

Graded Cardiac Response Criteria for Patients With Systemic Light Chain Amyloidosis

Journal of Clinical Oncology(2022)10.1200/jco.22.00643

N/A

0DataRank · unranked

90 citations

Angela Dispenzieri, Brendan Wisniowski, Giovanni Palladini, Paolo Milani, Giampaolo merlini +22 more

Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance)

Neuro-Oncology Advances(2022)10.1093/noajnl/vdac041

N/A

0DataRank · unranked

10 citations

S. Keith Anderson, Erin Twohy, Nicholas Butowski, Adı́lia Hormigo, David Schiff +11 more

Distribution of clonal hematopoiesis of indeterminate potential (CHIP) is not associated with race in patients with plasma cell neoplasms

Blood Cancer Journal(2022)10.1038/s41408-022-00706-5

N/A

0DataRank · unranked

4 citations

Shulan Tian, Susan M. Geyer, Neeraj Sharma, Celine M. Vachon, Yael Kusne +7 more

Alliance A059102: A randomized phase II U.S. intergroup study of CHO(E)P versus CC-486-CHO(E)P versus duvelisib-CHO(E)P in previously untreated, CD30-negative, peripheral T-cell lymphomas.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps7593

N/A

0DataRank · unranked

4 citations

Susan M. Geyer, Stefan K. Barta, Jennifer E. Amengual, Travis Dockter, Chadwick Wright +8 more

LBA53 Alliance A021602: Phase III, double-blinded study of cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET)

Annals of Oncology(2023)10.1016/j.annonc.2023.10.047

N/A

0DataRank · unranked

27 citations

Susan M. Geyer, F-S. Ou, Michael V. Knopp, Spencer C. Behr, Tyler Zemla +14 more

Current drug development and trial designs in neuro-oncology: report from the first American Society of Clinical Oncology and Society for Neuro-Oncology Clinical Trials Conference

The Lancet Oncology(2023)10.1016/s1470-2045(23)00005-0

N/A

0DataRank · unranked

26 citations

Mei‐Yin C. Polley, Laura Alder, Priscilla K. Brastianos, Carey K. Anders, Hussein A. Tawbi +9 more

Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303

Blood Advances(2023)10.1182/bloodadvances.2023010779

N/A

0DataRank · unranked

24 citations

Kilannin Krysiak, Cody A. Ramirez, Matthew Mosior, Marcus P. Watkins, Felicia Gomez +18 more

Alliance A021804: A prospective, multi-institutional phase II trial evaluating temozolomide versus temozolomide and olaparib for advanced pheochromocytoma and paraganglioma.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps4191

N/A

0DataRank · unranked

5 citations

Kimberly Perez, Susan M. Geyer, Maged Khalil, Aishwarya Vijendran, Andrea Kordaris-Corkill +9 more

Preliminary pharmacokinetic and safety data after a single intravenous infusion of Voyager-V1 (VV1, VSV-IFNβ-NIS) oncolytic virus in patients with relapsed refractory hematologic malignancies.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.e14594

N/A

0DataRank · unranked

2 citations

Adam Remick, Nabila Nora Bennani, Joselle Cook, Lianwen Zhang, Thomas E. Witzig +9 more

Alliance A022102: Randomized phase III trial of mFOLFIRINOX +/- nivolumab vs. FOLFOX +/- nivolumab for first-line treatment of metastatic HER2-negative gastroesophageal adenocarcinoma (GEA).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps4175

N/A

0DataRank · unranked

0 citations

Susan M. Geyer, Kelsey Klute, Jonathan Bleeker, Daniel A. King, Matthew R. Strickland +7 more

Ibrutinib added to standard conditioning and as maintenance therapy following autologous hematopoietic stem cell transplantation for relapsed or refractory activated-B-cell type Diffuse Large B-cell lymphoma: primary analysis of the US intergroup double-blind randomized phase III study Alliance A051301/BMT-CTN 1201

Leukemia & lymphoma/Leukemia and lymphoma(2025)10.1080/10428194.2025.2525982

N/A

0DataRank · unranked

2 citations

Olivia Bobek, Eric D. Hsi, Timothy S. Fenske, Patrick J. Stiff, Brian T. Hill +12 more

1712P Efficacy and safety of cabozantinib (CABO) for advanced lung and thymic neuroendocrine tumors (NET) after progression on prior therapy: Subgroup analysis of phase III CABINET Trial (Alliance A021602)

Annals of Oncology(2025)10.1016/j.annonc.2025.08.2340

N/A

0DataRank · unranked

1 citations

T. Zemla, Susan M. Geyer, Jonathan Strosberg, Þorvarður R. Hálfdánarson, Nikolaos A. Trikalinos +13 more

Radiomic signatures to estimate survival in patients with advanced hepatocellular carcinoma treated with sorafenib: Cancer and Leukemia Group B 80802 (Alliance)

ESMO Open(2025)10.1016/j.esmoop.2025.105848

N/A

0DataRank · unranked

1 citations

Susan M. Geyer, Andrew B. Nixon, Federico Innocenti, Q. Shi, Steven Jacobson +15 more

Alliance A071701: Genomically guided treatment trial in brain metastases.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.tps2573

N/A

0DataRank · unranked

7 citations

Erin Twohy, Carey K. Anders, A. John Iafrate, Peter A. Kaufman, Justine V. Cohen +11 more

Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study

UNC Libraries(2020)10.17615/q2fj-2t55

N/A

0DataRank · unranked

0 citations

Flora Mulkey, Robert Z. Orlowski, Ben L. Sanford, Richard A. Larson, Susan M. Geyer +5 more

Alliance/CALGB 80802: Impact of hepatitis C (HCV) on doxorubicin (DO) + sorafenib (S) versus S in patients (pts) with advanced hepatocellular carcinoma (aHCC).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.3_suppl.325

N/A

0DataRank · unranked

2 citations

Susan M. Geyer, Andrew B. Nixon, Federico Innocenti, Qian Shi, Sawyer Jacobson +12 more

Radiomic signatures to predict survival in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib +/- doxorubicin: Correlative science from CALGB 80802 (Alliance).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.3_suppl.343

N/A

0DataRank · unranked

1 citations

Susan M. Geyer, Andrew B. Nixon, Federico Innocenti, Qian Shi, Sawyer Jacobson +12 more

Genetic predictor of severe sorafenib-induced diarrhea and hand-foot syndrome (HFS).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.3030

N/A

0DataRank · unranked

1 citations

Susan M. Geyer, Jin Wang, Amy S. Etheridge, Stefanie Denning, Alessandro Racioppi +7 more

Susan M. Geyer

Indexed papers

Top data-sharing exemplar

Papers